PDF herunterladen
Horm Metab Res
DOI: 10.1055/a-2379-1326
Original Article: Endocrine Care

The Value of lncRNAs as a Biomarker for the Diagnosis of Gestational Diabetes: A Meta-Analysis

Yang Fan‡
1   Peopleʼs Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Ningxia, China
,
Xin Chen‡
2   Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China (Ringgold ID: RIN47879)
,
Song Yang
3   General Practice, Hefei First Peopleʼs Hospital, Hefei, China
,
Hongxia Tu
4   Gynaecology and Obstetrics, The General Hospital of Western Theater Command PLA, Chengdu, China
,
Youyi Zhang
4   Gynaecology and Obstetrics, The General Hospital of Western Theater Command PLA, Chengdu, China
,
Mingyi Wang
4   Gynaecology and Obstetrics, The General Hospital of Western Theater Command PLA, Chengdu, China
,
Jingying Jiang
5   Gynaecology and Obstetrics, Wuxi Maternity and Child Health Care Hospital (Affiliated Women's Hospital of Jiangnan University), Wuxi, China
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Gestational diabetes mellitus (GDM) is a common metabolic disorder in pregnancy and leads to serious harm to the mother and the fetus. A variety of lncRNAs play a key role in GDM. This meta-analysis was performed to explore the potential value of lncRNAs in GDM diagnosis. Articles correlated with lncRNA and GDM were screened from Embase, Medline, EBSCO, PubMed, Chinese National Knowledge Infrastructure, and WanFang databases. Summary receiver operator characteristic (SROC) was performed to evaluate the pooled area under curve (AUC). Forest plot was conducted to calculate the sensitivity, specificity, diagnostic likelihood ratio (LR), diagnostic score, and diagnostic odds ratio (DOR). Deeks’ funnel plot was utilized to evaluate the publication bias. Eleven articles containing 12 tests (1060 GDM patients and 1066 controls) were included in this meta-analysis. AUC (0.89, 95%CI=0.86–0.92), sensitivity (0.84, 95%CI=0.80–0.87), and specificity (0.81, 95%CI=0.77–0.85)of the SROC curve showed a high diagnostic value of lncRNA for GDM. Positive LR (PLR 4.40, 95%CI=3.45–5.60) and negative LR (NLR 0.20, 95%CI=0.15–0.26) results indicated that the diagnosis of lncRNA for GDM had low clinical utility. Diagnostic score (3.09, 95%CI=2.62–3.57) and DOR (22.04, 95%CI=13.68–35.51) results suggested lncRNAs have good discriminative effect on GDM. Heterogeneity was significantly higher, but not induced by the subgroups. LncRNAs had high diagnostic value and good discriminative effect for GDM, but the clinical utility was not high. This meta-analysis study offers a potential target for GDM diagnosis.

Keywords

gestational diabetes mellitus - diagnosis - SROC


Publikationsverlauf

Eingereicht: 03. Juni 2024

Angenommen nach Revision: 29. Juli 2024

Artikel online veröffentlicht:
14. Oktober 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Sweeting A, Wong J, Murphy HR. et al. A clinical update on gestational diabetes mellitus. Endocr Rev 2022; 43: 763-793
    CrossrefPubMedGoogle Scholar
  • 2 Atlaw D, Sahiledengle B, Assefa T. et al. Incidence and risk factors of gestational diabetes mellitus in Goba town, Southeast Ethiopia: a prospective cohort study. BMJ Open 2022; 12: e060694
    CrossrefPubMedGoogle Scholar
  • 3 Lende M, Rijhsinghani A. Gestational diabetes: overview with emphasis on medical management. Int J Environ Res Public Health 2020; 17: 9573
    CrossrefPubMedGoogle Scholar
  • 4 Li G, Wei T, Ni W. et al. Incidence and eisk factors of gestational diabetes mellitus: a prospective cohort study in Qingdao, China. Front Endocrinol (Lausanne) 2020; 11: 636
    CrossrefPubMedGoogle Scholar
  • 5 Vounzoulaki E, Khunti K, Abner SC. et al. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ 2020; 369: m1361
    CrossrefPubMedGoogle Scholar
  • 6 Lajili O, Htira Y, Temessek A. et al. Incidence of maternal and fetal outcomes in women with gestational diabetes. Tunis Med 2022; 100: 241-246
    PubMedGoogle Scholar
  • 7 Meek CL, Devoy B, Simmons D. et al. Seasonal variations in incidence and maternal-fetal outcomes of gestational diabetes. Diabet Med 2020; 37: 674-680
    CrossrefPubMedGoogle Scholar
  • 8 Wicklow B, Retnakaran R. Gestational diabetes mellitus and its implications across the life span. Diabetes Metab J 2023; 47: 333-344
    CrossrefPubMedGoogle Scholar
  • 9 Bennett G, King N, Redfern K. et al. Supervised physical activity and the incidence of gestational diabetes mellitus: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2023; 36: 2155043
    CrossrefPubMedGoogle Scholar
  • 10 Ergin A, Turkay U, Ozdemir S. et al. Age at menarche: risk factor for gestational diabetes. J Obstet Gynaecol 2022; 42: 680-686
    CrossrefPubMedGoogle Scholar
  • 11 Mehmood S, Ye C, Hanley AJ. et al. Impact of the diagnosis of gestational diabetes on maternal physical activity after pregnancy. Diabetes Obes Metab 2024; 26: 1207-1215
    CrossrefPubMedGoogle Scholar
  • 12 Teede HJ, Bailey C, Moran LJ. et al. Association of antenatal diet and physical activity-based interventions with gestational weight gain and pregnancy outcomes: a systematic review and meta-analysis. JAMA Intern Med 2022; 182: 106-114
    CrossrefPubMedGoogle Scholar
  • 13 Filardi T, Catanzaro G, Mardente S. et al. Non-coding RNA: role in gestational diabetes pathophysiology and complications. Int J Mol Sci 2020; 21: 4020
    CrossrefPubMedGoogle Scholar
  • 14 Alipoor B, Nikouei S, Rezaeinejad F. et al. Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets. J Endocrinol Invest 2021; 44: 2015-2041
    CrossrefPubMedGoogle Scholar
  • 15 Guiyu S, Quan N, Ruochen W. et al. LncRNA-SNX17 promotes HTR-8/SVneo proliferation and invasion through miR-517a/IGF-1 in the placenta of diabetic macrosomia. Reprod Sci 2022; 29: 596-605
    CrossrefPubMedGoogle Scholar
  • 16 Bian G, Xue Y, Liu Y. et al. Role of lncRNA-MEG8/miR-296-3p axis in gestational diabetes mellitus. Nephrology (Carlton) 2022; 27: 994-1002
    CrossrefPubMedGoogle Scholar
  • 17 Zhang Y, Qu L, Ni H. et al. Expression and function of lncRNA MALAT1 in gestational diabetes mellitus. Adv Clin Exp Med 2020; 29: 903-910
    CrossrefPubMedGoogle Scholar
  • 18 Li J, Du B, Geng X. et al. lncRNA SNHG17 is downregulated in gestational diabetes mellitus (GDM) and has predictive values. Diabetes Metab Syndr Obes 2021; 14: 831-838
    CrossrefPubMedGoogle Scholar
  • 19 Lu J, Wu J, Zhao Z. et al. Circulating lncRNA serve as fingerprint for gestational diabetes mellitus associated with risk of macrosomia. Cell Physiol Biochem 2018; 48: 1012-1018
    CrossrefPubMedGoogle Scholar
  • 20 Zhang Y, Wu H, Wang F. et al. Long non-coding RNA MALAT1 expression in patients with gestational diabetes mellitus. Int J Gynaecol Obstet 2018; 140: 164-169
    CrossrefPubMedGoogle Scholar
  • 21 Leng B, Chen F, Li M. et al. Plasma Lnc-UCA1/miR-138 axis as a potential biomarker for gestational diabetes mellitus and neonatal prognosis. Ginekol Pol 2023; 94: 845-851
    CrossrefPubMedGoogle Scholar
  • 22 Su R, Wu X, Ke F. Long Non-coding RNA HOTAIR expression and clinical significance in patients with gestational diabetes. Int J Gen Med 2021; 14: 9945-9950
    CrossrefPubMedGoogle Scholar
  • 23 Li Y, Liu L. LncRNA OIP5-AS1 Signatures as a biomarker of gestational diabetes mellitus and a regulator on trophoblast cells. Gynecol Obstet Invest 2021; 86: 509-517
    CrossrefPubMedGoogle Scholar
  • 24 Li Y, Yuan X, Shi Z. et al. LncRNA XIST serves as a diagnostic biomarker in gestational diabetes mellitus and its regulatory effect on trophoblast cell via miR-497-5p/FOXO1 axis. Cardiovasc Diagn Ther 2021; 11: 716-725
    CrossrefPubMedGoogle Scholar
  • 25 Cao H, Wu P, Shi Q. et al. The expression level and clinical significance of lncRNA-SNX17 in the serum of pregnant women with gestational diabetes mellitus. Chin J Birth Health Heredity 2022; 30: 870-875
    PubMedGoogle Scholar
  • 26 Ma D, Bai L. Expression and significance of lncRNA-HOTTIP and miR-21 in serum of patients with gestational diabetes mellitus. J Clin Hematol 2022; 35: 108-111 116
    PubMedGoogle Scholar
  • 27 Xie F, Li Q, Zhao A. et al. Value of expression level of lncRNA-p3134 in diagnosing gestational diabetes mellitus. J Clin Med Pract 2021; 25: 106-110
    PubMedGoogle Scholar
  • 28 Ju J, Yi M. Expression of secreted frizzled related protein 5, long non-coding RNA transcripts associated with metastasis in human lung adenocarcinoma and adipokine retinal protein-1 in gestational Chin. J Hum Sexual 2021; 30: 96-99
    PubMedGoogle Scholar
  • 29 Gari A, Alshamlan SA, Alghamdi M. et al. Assessment of womenʼs awareness of the effects of gestational diabetes mellitus on the mother and fetus in Saudi Arabia: a cross-sectional study. Cureus 2024; 16: e56969
    PubMedGoogle Scholar
  • 30 Bedell S, Hutson J, de Vrijer B. et al. Effects of maternal obesity and gestational diabetes mellitus on the placenta: current knowledge and targets for therapeutic interventions. Curr Vasc Pharmacol 2021; 19: 176-192
    CrossrefPubMedGoogle Scholar
  • 31 Ye W, Luo C, Huang J. et al. Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis. BMJ 2022; 377: e067946
    CrossrefPubMedGoogle Scholar
  • 32 Xu Y, Kang X, Liu H. et al. LncRNA XIST promotes insulin resistance in gestational diabetes mellitus via the microRNA-181b-5p/NDRG2 axis. Gen Physiol Biophys 2023; 42: 443-455
    CrossrefPubMedGoogle Scholar